Skip to main
CRBU

Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences (CRBU) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Caribou Biosciences is projected to have a positive outlook in the coming years, with its 1Q26 net loss of $0.26 per share being narrower than previously estimated and a projected full-year 2026 net loss of $1.23 per share. With a solid cash position of $118.6M and upcoming catalysts such as longer follow-up data from the Phase 1 ANTLER trial and initial dose expansion data for CB-011, the company is set to make strides in developing allogeneic CAR-T cell therapies.

Bears say

Caribou Biosciences is currently a risky investment due to its negative cash flow, low probability of approval for its lead assets, and potential delays in advancing these assets to the next stage. Additionally, the company faces long-term dilution risk and a competitive landscape, which could hinder its overall success. Upcoming catalysts may provide some insight into the efficacy of its lead assets, but these are still several years away.

Caribou Biosciences (CRBU) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Caribou Biosciences (CRBU) Forecast

Analysts have given Caribou Biosciences (CRBU) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Caribou Biosciences (CRBU) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Caribou Biosciences (CRBU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.